Prothena Corp Public (PRTA) EBITDA Margin (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly EBITDA Margin came in at 58.8% in Q1 2026, up 237778.0% year-on-year from N/an in Q1 2025, and up 100.05% quarter-over-quarter from 115252.38% in Q4 2025.
Prothena Corp Public (PRTA) EBITDA Margin (2012 - 2026) Analysis & Trends
Prothena Corp Public's EBITDA Margin history runs 15 years deep, the most recent figure standing at 58.8% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 237778.0% year-over-year to 58.8% in Q1 2026; TTM through Mar 2026 was 205.43%, a 10493.0% decrease from a year earlier, with the FY2025 full-year figure at 2216.44%, down 210208.0% from the prior year.
- EBITDA Margin rose to 58.8% in Q1 2026 per PRTA's latest filing, from 115252.38% in the prior quarter.
- Across five years, EBITDA Margin topped out at 58.8% in Q1 2026 and bottomed at 163056.0% in Q1 2024.
- The 5-year median for EBITDA Margin is 2596.82% (2023), against an average of 19588.65%.
- Across the five-year window, EBITDA Margin slumped 16045918 bps in 2024 and surged 16073701 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 0.14% in 2022, then slumped by 17227855 bps to 24846.52% in 2023, then jumped by 88 bps to 3056.85% in 2024, then slumped by 3670 bps to 115252.38% in 2025, then soared by 100 bps to 58.8% in 2026.
- Per Business Quant, the three latest PRTA EBITDA Margin figures stand at 58.8% (Q1 2026), 115252.38% (Q4 2025), and 1666.25% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - | 58.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.80% |
| Dec 31, 2025 | -115,252.38% |
| Sep 30, 2025 | -1,666.25% |
| Jun 30, 2025 | -1,914.39% |
| Mar 31, 2025 | -2,318.99% |
| Dec 31, 2024 | -3,056.85% |
| Sep 30, 2024 | -6,857.01% |
| Jun 30, 2024 | 44.22% |
| Mar 31, 2024 | -163,056.00% |
| Dec 31, 2023 | -24,846.52% |
| Sep 30, 2023 | 12.15% |
| Jun 30, 2023 | -1,654.74% |
| Mar 31, 2023 | -2,596.82% |
| Dec 31, 2022 | -0.14% |
| Sep 30, 2022 | -3,317.86% |
| Jun 30, 2022 | -3,293.37% |
| Mar 31, 2022 | -3,290.89% |
| Dec 31, 2021 | -2,823.55% |
| Sep 30, 2021 | 78.48% |
| Jun 30, 2021 | 46.53% |